title: Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184.
abstract: OBJECTIVE
  Current positron emission tomography (PET) radioligands for detection of Abeta amyloid in Alzheimer's disease (AD) are not ideal for quantification. To improve the signal to noise ratio we have developed the radioligand [(11)C]AZD2184 and report here the first clinical evaluation.
  
  
  METHODS
  Eight AD patients and four younger control subjects underwent 93-min PET measurements with [(11)C]AZD2184. A ratio approach using the cerebellum as reference region was applied to determine binding parameters.
  
  
  RESULTS
  Brain uptake of [(11)C]AZD2184 peaked within 1 min at 3-4% of injected radioactivity. AD patients had high radioactivity in cortical regions while controls had uniformly low radioactivity uptake. Specific binding peaked within 30 min at which time standardized uptake value ratios (SUVR) ranged between 1.19 and 2.57.
  
  
  CONCLUSIONS
  [(11)C]AZD2184 is a promising radioligand for detailed mapping of Abeta amyloid depositions in Alzheimer's disease, due to low non-specific binding, high signal to background ratio and reversible binding as evident from early peak equilibrium.
authors.affiliation: AstraZeneca R&D, Neuroscience Therapy Area, 151 85 Södertälje, Sweden. svante.nyberg@astrazeneca.com
authors.forename: Svante
authors.initials: S
authors.lastname: Nyberg
authors.forename: Maria Eriksdotter
authors.initials: ME
authors.lastname: Jönhagen
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Cselényi
authors.forename: Christer
authors.initials: C
authors.lastname: Halldin
authors.forename: Per
authors.initials: P
authors.lastname: Julin
authors.forename: Hans
authors.initials: H
authors.lastname: Olsson
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Freund-Levi
authors.forename: Jan
authors.initials: J
authors.lastname: Andersson
authors.forename: Katarina
authors.initials: K
authors.lastname: Varnäs
authors.forename: Samuel
authors.initials: S
authors.lastname: Svensson
authors.forename: Lars
authors.initials: L
authors.lastname: Farde
mesh_terms: D000328:Adult; D000368:Aged; D000544:Alzheimer Disease / Q000000981:diagnostic imaging* / Q000378:metabolism*; D000631:Aminopyridines / Q000737:chemistry / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D052160:Benzothiazoles / Q000737:chemistry / Q000378:metabolism; D002250:Carbon Radioisotopes; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D055815:Young Adult
chemical_list: C539976:2-(6-(methylamino)pyridin-3-yl)-1,3-benzothiazol-6-ol; D000631:Aminopyridines; D016229:Amyloid beta-Peptides; D052160:Benzothiazoles; D002250:Carbon Radioisotopes